Rezolute, Inc.

NASDAQ:RZLT

4.87 (USD) • At close September 18, 2024
Bedrijfsnaam Rezolute, Inc.
Symbool RZLT
Munteenheid USD
Prijs 4.87
Beurswaarde 269,588,103
Dividendpercentage 0%
52-weken bereik 0.72 - 6.1
Industrie Biotechnology
Sector Healthcare
CEO Mr. Nevan Charles Elam J.D.
Website https://www.rezolutebio.com

An error occurred while fetching data.

Over Rezolute, Inc.

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic

Vergelijkbare Aandelen

Greenwich LifeSciences, Inc. logo

Greenwich LifeSciences, Inc.

GLSI

14.17 USD

Selecta Biosciences, Inc. logo

Selecta Biosciences, Inc.

SELB

0.881 USD

FONAR Corporation logo

FONAR Corporation

FONR

17.4 USD

CytomX Therapeutics, Inc. logo

CytomX Therapeutics, Inc.

CTMX

1.19 USD

Achilles Therapeutics plc logo

Achilles Therapeutics plc

ACHL

0.71 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)